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A novel deletion mutation in the adenosine deaminase RNA-speciﬁc gene in
a Taiwanese patient with dyschromatosis symmetrica hereditariaCase report
A 10-year-old boy was referred to our dermatology department
with mottled hyperpigmented and hypopigmented macules over
the upper extremities and neck for about 5 years (Figure 1). There
was no history of prolonged sun exposure. The skin lesions were
more prominent in summer and improved in winter. He was other-
wise healthy except for allergic rhinitis. No other family members
had similar skin lesions.
Skin biopsies were done from a hyperpigmented macule and
a hypopigmented macule. The hyperpigmented lesion showed
basal hyperpigmentation; the density and morphology of basal
melanocytes appeared normal as demonstrated by immunostain-
ing for Melan-A. The hypopigmented lesion showed basal hypopig-
mentation with reduced number of Melan-A-positive basal
melanocytes. The clinical and pathologic ﬁndings are consistent
with dyschromatosis symmetrica hereditaria (DSH).
Polymerase chain reaction ampliﬁcation and automated
sequencing
Genomic DNA was extracted from peripheral blood of the patient
with informed consent from patient’s parents. DNA sample was
then subjected to mutation screening by ampliﬁcation of segments
of adenosine deaminase RNA-speciﬁc (ADAR) gene. For polymerase
chain reaction (PCR) ampliﬁcation, approximately 200 ng of
genomic DNA, 12.8 pmol/L of each primer, 10 mmole/L dNTP, and
1.25 U of AmpliTaq Gold (Perkin Elmer, Roche Molecular Systems,
Inc., Branchburg, NJ, USA) were used in a total volume of 50 mL.
The oligonucleotide primers designed to amplify the mutation in
Exon 7 of the ADAR gene were: forward primer, 50-GTAATACCTGFigure 1 Our patient, a 10-year-old boy, presented with mottled hyperpigmented and hy
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doi:10.1016/j.dsi.2010.11.001GATGTGGCAC-30 and reverse primer, 50-GTCCCAGTTACTGCTCT
CTC-30. The product size was 556 base pairs. The ampliﬁcation
conditions were 94C for 5 minutes followed by 35 cycles of 94C
for 45 seconds, annealing temperature (50C) for 45 seconds and
72C for 45 seconds, and ﬁnal extension at 72C for 10 minutes.
The PCR products were examined on 2% agarose gel. The PCR
product was subjected to direct automated sequencing (377 ABI
Advanced Biotechnologies, Columbia, MD, USA).
A deletion mutation, c.2433delA (p.T811fs), resulting in prema-
ture termination code (PTC þ33 aa) was found (Figure 2).
Discussion
We described the clinicopathologic ﬁndings of DSH in a Taiwanese
boy. Thediagnosis ofDSHwas supportedbymutationanalysis,which
detected a novel deletion mutation in the ADAR gene. The family
pedigree suggested that our patient is a sporadic case of DSH. DSH
(OMIM 127400), also known as reticulate acropigmentation of
Dohi, is a pigmentary genodermatosis characterized by a mixture
of hyperpigmented and hypopigmented macules of various sizes
on the dorsal aspects of the extremities and freckle-like macules on
the face. It was ﬁrst described by Toyama in a Japanese family in
1929 and was later reported mainly in Japanese and Chinese
patients,1,2 with a few cases reported among Koreans, Indians, Euro-
peans, and South Americans. DSH shows autosomal dominant
pattern of inheritance, but sporadic cases have been reported.
ADAR gene is also known as adenosine deaminase acting on
RNA 1 gene or double-stranded RNA-speciﬁc adenosine deaminase
gene, which encodes ADAR.2 The gene contains six functional
domains, including two Z-DNA-binding domain in adenosine deam-
inases (Z-alpha), three double-stranded RNA bindingmotifs (DSRM),popigmented macules on the (A) neck, (B) right upper arm, and (C) left lower arm.
. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 2 Automated DNA sequencing of adenosine deaminase RNA-speciﬁc gene
reveals (A) a single nucleotide deletion mutation (2433delA) in Exon 7 and (B) a normal
sequence from control.
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(ADEAMc). The ADEAMc encodes the amino acid residues from
886 to 1221, which is only about 27% of the total 1226 amino acid
residues in length. However, 63 different mutations have been
reported in this domain, accounting for nearly 70% of the known
93 mutations for DSH.
ADAR catalyzes the deamination of adenosine to inosine in
dsRNA, which produces changes in the codon or splice site and
destabilizes the dsRNA helix. Two different concepts, namely hap-
loinsufﬁciency and a dominant-negative effect because of the
absence of homodimerization,3,4 have been proposed as the possible
molecular pathogenesis of DSH. The adenosine to inosine alteration
has been demonstrated to promote the survival and function of
many tissues, including vertebra, heart, liver, and brain.5 ADAR is
also expressed ubiquitously all over the skin. Miyamura et al6
speculated that distal migration of melanoblasts from the neural
crest to the skin during development is associated with a greater
reduction in ADAR activity at anatomic sites most distant from the
neural crest. Failure of adenosine to inosine RNA editing may cause
melanoblasts to differentiate into either hyperactive or hypoactive
melanocytes, which then colonize the skin in an irregular distribu-
tion. This may explain the mottled hyperpigmented and hypopig-
mented macular dyschromatosis of DSH and their preferential
distribution on the backs of the hands and feet.
DSH usually begins during infancy or early childhood. The clin-
ical manifestation varies among different races or countries. In the
two reviews of the 185 reported cases from Japan and the 136
reported cases from China,1,2 the latter showed extraordinary
pigmentation change on the neck and the chest in addition to the
typical distribution of the extremities and face observed in the
former. The skin manifestation in the present patient as well as
our other patients7,8 are similar to those reported fromChina. Never-
theless, no obvious correlation between genotype and phenotype
has been discovered yet. Besides, positive family history was noted
in 77.6% of the Japanese patients. The data are similar to the result as
76.1%, which we may obtain in the available literature in recent 5
years if we only include the cases of reported novel mutation.
The mutation in our patient is a novel single nucleotide deletion
mutation, c.2433delA, in the Exon 7 of ADAR gene, which is
expected to result in frameshift mutation, p.T811fs, and premature
termination codon 33 amino acids downstream. Similar frameshift
mutation at the same amino acid has been reported, but they
included two nucleotide changes as c.2433 _2434delAG and the
premature termination codon was 30 amino acids downstream.9
The histology of DSH is characterized by abundant melanin
pigment in the keratinocytes and melanocytes in thehyperpigmented macules and reduced melaninization in hypopig-
mented macules.1 Masson-Fontana staining and immunostaining
for S-100 or Melan-A are helpful in assessing epidermal melanini-
zation andmelanocytic density. In our experience, Melan-A is supe-
rior to S100 in displaying better morphology and larger number of
melanocytes in the epidermis. In the present case, the basal mela-
nocytes appeared normal in the morphology and number in the
hyperpigmented macule but were small in size and reduced in
number in the hypopigmented macule. We did not perform elec-
tron microscopy in the present case; however, the ultrastructural
study in one of our previous cases of DSH revealed large numbers
of fully melanized melanosomes of varying sizes, often in large
clusters, in the basal keratinocytes of hyperpigmented macules.7
Melanocytes themselves were not easily found but dendrites con-
taining melanosomes could be seen readily. In the hypopigmented
macule, most keratinocytes contained few or no melanosomes, and
melanocytes were either small or not easily visible.
Effective treatment for DSH has not been established; however,
we have previously observed a signiﬁcant clinical improvement in
the dyspigmentation in a DSH patient after strict sun protection.8
The more homogenous appearance of the skin color might be
because of the reduced pigmentation of the hyperpigmented
components. However, the role of sunlight in the pathogenesis
and/or progression of pigment alterations as well as the potential
beneﬁcial effect of strict sunprotectionneed to be further elucidated.Acknowledgments
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